Browse studies

Find your next paid study

92 recruiting studies matching your filters

Newest first Highest paying

Phase 1

Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation From an HLA-Mismatched Donor (7/8) With Orca-T

The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.

Acute Myeloid LeukemiaAcute Lymphoid LeukemiaMixed Phenotype Acute Leukemia+1 more

Estimated

~$10 – $6,250

Stanford UniversityNCT06551584

Phase 1

Cytokine-induced Memory-like Natural Killer Cell Therapy After Hematopoietic Stem Cell Transplantation for Eradication of Measurable Residual Disease, a Phase I/Ib Clinical Trial

The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleuki…

Acute Myeloid LeukemiaLeukemiaLeukemia, Myeloid+3 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT06138587

Phase 1

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) wit…

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative Neoplasm+1 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT04024761

Phase 1

A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hemato…

Relapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic Malignancies+1 more

Estimated

~$10 – $7,500

Institut de Recherches Internationales ServierNCT02074839

Phase 1

A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Severe Renal Impairment and Cancer Patients With Normal Renal Function

This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a f…

Acute Myeloid LeukemiaMyelodysplastic Syndromes

Estimated

~$10 – $8,750

Taiho Oncology, Inc.NCT04953897

Phase 1

Proof-Of-Concept Study of Metabolically Optimized, Non-Cytotoxic 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Another term for myelodysplastic syndrome is bone marrow failure. The bone marrow is where components of blood such as red cells, platelets and white cells are…

Myelodysplastic SyndromesMDS/MPN Crossover Syndromes

Estimated

~$10 – $7,500

Benjamin TomlinsonNCT04187703

Investigation of the Genetics of Hematologic Diseases

The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment o…

Bone Marrow Failure SyndromesErythrocyte DisorderLeukocyte Disorder+10 more

Estimated

~$10 – $750

St. Jude Children's Research HospitalNCT02720679

Phase 2

A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants With Anemia Due to Low-risk Myelodysplastic Syndrome

The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial wil…

Myelodysplastic Syndromes

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT06847867

Phase 1

Phase Ib Study of Anti-CD3 x Anti-CD33 Bispecific Antibody (CD33Bi) Armed Fresh Peripheral Blood Mononuclear Cells (CD33 FPBMC) in Patients With Measurable Residual Disease (MRD)+ Acute Myeloid Leukemia or Myelodysplastic Syndrome

The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peri…

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm

Estimated

~$10 – $6,250

University of VirginiaNCT07270978

Phase 2

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients …

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaJuvenile Myelomonocytic Leukemia+4 more

Estimated

~$10 – $6,250

University of FloridaNCT05800210

Phase 2

Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies

The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and yo…

Acute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndromes+5 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07566377

Phase 1

A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Moderate and Severe Hepatic Impairment

This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known …

Acute Myeloid LeukemiaMyelodysplastic Syndromes

Estimated

~$10 – $8,750

Taiho Oncology, Inc.NCT04953910